Journal article
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study
Abstract
BackgroundThe EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults.MethodsThis was a multinational, single-dose, open-label, phase I study to describe the pharmacodynamics (PD), pharmacokinetics (PK) and safety of a single bodyweight-adjusted rivaroxaban dose in children aged 0.5–18 years. Children who had completed …
Authors
Kubitza D; Willmann S; Becka M; Thelen K; Young G; Brandão LR; Monagle P; Male C; Chan A; Kennet G
Journal
Thrombosis Journal, Vol. 16, No. 1,
Publisher
Springer Nature
Publication Date
12 2018
DOI
10.1186/s12959-018-0186-0
ISSN
1477-9560